Vascular Endothelial Growth Factor (VEGF) Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
- Transparency Market Research
Vascular endothelial growth factor (VEGF) is a process of formation of new blood vessels from endothelial cells or from pre-existing vessels. VEGF’s normal function is during embryonic development, formation of new blood vessels after injury, in muscles after exercise, and as a bypass for a blocked vessel. Overexpression of VEGF can be fatal as they can grow into cancerous cells. VEGF plays both beneficial and damaging roles in organisms. It takes circulating endothelial precursor cells and acts as a growth medium for immature tumor cells. The affinity of VEGF toward endothelial cells is mediated through VEGF-specific tyrosine kinase receptors VEGFR-1, VEGFR-2, and VEGFR-3. Hence, VEGF and its receptors play a major role in the growth of tumor cells. The endotheliotropic property of VEGF causes a major concern for developing vascular endothelial growth factor receptor (VEGFR) inhibitors. The VEGF family in mammals comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PIGF. Out of these, VEGF-A is responsible for angiogenesis and migration and mitosis of endothelial cells. Many therapeutic strategies are developed for inhibiting the signal transduction of VEGF. Some of the therapeutic options are monoclonal antibodies against VEGF or VEGFR, soluble VEGF and VEGFR hybrids, and tyrosine kinase inhibitors.
Vascular endothelial growth factor inhibitors are also termed as angiogenesis inhibitors. They inhibit the growth of new blood vessels. Angiogenesis inhibitors are effective in the treatment of cancer, macular degeneration in the eye, and diseases that involve proliferation of blood vessels. VEGF or angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors are involved in regulating the process of blood vessel formation. They are derived from cellular matrix and basement protein. Among the factors responsible for angiogenesis, VEGF is the most potent and has high expression in ovarian, endometrial, and cervical cancer. Inhibition of angiogenesis by VEGF requires anti-VEGF/ anti-angiogenesis factors, which reduce the production of pro- angiogenic factors, thereby preventing them from binding to their receptors. The commonly used therapy for VEGF pathway inhibition is monoclonal antibody against VEGF or VEGFR, soluble VEGFR hybrids, and tyrosine kinase inhibitors. Monoclonal antibody Bevacizumab is widely used for treatment.
Global increase in the prevalence of cancer and recognition of therapeutic opportunities offered by oncology treatments have driven the pharmaceutical industry to develop new agents to treat cancer. According to WHO, new cancer cases are expected to rise by 70% in the coming two decades. Approximately 60% of malignant tumors express high concentrations of VEGF. Therefore, therapeutic options to inhibit the VEGF tumor causing pathway has become a major concern for all researchers. One of the factors restraining VEGF inhibitors from becoming a silver bullet in the treatment of cancer is that angiogenesis is not the only factor causing tumors. Other restraints include the side effects caused by VEGF inhibitors such as bleeding and increased blood pressure.
The VEGF inhibitors market can be segmented based on mode of action of the drug, route of administration, end-user, and geography. In terms of mode of action of the drug, the VEGF inhibitors market can be classified into tyrosine kinase inhibitors, monoclonal antibodies, and VEGFR hybrids. Tyrosine kinase inhibitors inhibit the adenosine triphosphate binding sites. Monoclonal antibodies bind to VEGF-A, preventing it from binding to receptors and activating the signaling cascades that lead to angiogenesis. VEGFR hybrids act as decoy receptors and prevent binding of the ligand to its natural receptors. Based on route of administration, the VEGF inhibitors market can be classified into oral and intravenous. In terms of end-user, the VEGF inhibitors market can be divided into hospitals, ambulatory surgical centers, and cancer research institutes. Based on geography, the VEGF inhibitors market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The tyrosine kinase inhibitor segment is a dominant segment of the VEGF inhibitors market in North America, followed by Asia Pacific and Europe. China is projected to drive the VEGF inhibitors market in Asia Pacific by providing expansion opportunities to upcoming companies. Countries such as China, India, and South Asian countries are expected to dominate the VEGF inhibitors market in Asia Pacific. According to WHO, cancer prevalence is estimated to rise at a rapid pace in Africa, Asia, and the U.S.
The top layers in the VEGF inhibitors market are Pfizer, Inc., Novartis AG, AstraZeneca plc, Bayer AG, Merck & Co., Inc., Genentech, Inc. (Roche), Eli Lilly & Company, Sanofi, GlaxoSmithKline plc, Bristol-Myers-Squibb Company, and Boehringer Ingelheim GmbH.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Healthcare
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017